Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sublingual recombinant Bet v 1 immunotherapy in birch pollen rhinoconjunctivitis
2007-007869-21Phase 2Completed
- Sponsor
- Stallergenes Greer
- Start
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant Bet v 1 in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Stallergenes Greer. Primary endpoint: Primary efficacy variable. Started Jun 2008; status: completed.
02
Drugs
recombinant Bet v 1
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2007-007869-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007869-21.